|
|
Post by victoria on May 10, 2016 18:07:19 GMT -5
|
|
|
|
Post by agedhippie on May 10, 2016 20:44:35 GMT -5
My ideal company for this would be Mannkind's product and Dance's management. Dance effectively have a Chinese pharma pushing the drug though approvals over there who will then manufacture, market and sell it. That's pushed them in front of Mannkind for selling to the Chinese market. It looks like they are bypassing the US market in favor of the Chinese market.
btw. Dongbao make Western drugs, Chinese drugs, biologicals, oh and plastic building materials!
|
|
|
|
Post by peppy on May 11, 2016 10:38:15 GMT -5
My ideal company for this would be Mannkind's product and Dance's management. Dance effectively have a Chinese pharma pushing the drug though approvals over there who will then manufacture, market and sell it. That's pushed them in front of Mannkind for selling to the Chinese market. It looks like they are bypassing the US market in favor of the Chinese market. btw. Dongbao make Western drugs, Chinese drugs, biologicals, oh and plastic building materials!JNJ drugs and plastics also. www.jnj.com/healthcare-products/consumer
|
|
|
|
Post by brotherm1 on May 16, 2016 1:38:03 GMT -5
So this Dance's insulin inhalation technology stems from their take over of Exubera with their intent to make an improved applicator. I'm not getting good search results on the subject. Does anyone know what the applicator looks like? Is Dance's product still in phase two trials? Speaking of Exubera, does anyone recall how much Dance paid to Pfizer for it?
|
|
|
|
Post by liane on May 16, 2016 4:25:42 GMT -5
I think much of what you are looking for is right on Dance's webpage, dancebiopharm.com/. Dance's product, still in P2 I believe, is completely different from Exubera. Exubera was a dry powder, Dance is nebulized - a liquid mist. I think the only connection is some people that worked on Exubera now work on Dance. |
|
|
|
Post by lakon on May 16, 2016 9:17:06 GMT -5
I think much of what you are looking for is right on Dance's webpage, dancebiopharm.com/. Dance's product, still in P2 I believe, is completely different from Exubera. Exubera was a dry powder, Dance is nebulized - a liquid mist. I think the only connection is some people that worked on Exubera now work on Dance. I'm not sure that I agree with you about being completely different. Is ice completely different from water? (I'm fairly certain that the API is the same -- insulin hexamer. Now, a monomer would be innovative, as long as it's human. Don't want any of those analogs burning through the lungs.) |
|
|
|
Post by liane on May 16, 2016 9:28:35 GMT -5
Yes, still hexamer pharmacokinetics. But totally different mode of delivery.
|
|
|
|
Post by cjm18 on Apr 11, 2018 10:59:15 GMT -5
|
|
|
|
Post by mnkdfann on Apr 11, 2018 11:31:08 GMT -5
Which item on that page are you referring to? The most recent I see is from early March, about a Board appointment. |
|
|
|
Post by peppy on Apr 11, 2018 12:06:28 GMT -5
|
|
|
|
Post by agedhippie on Apr 11, 2018 12:15:59 GMT -5
There isn't one. I think they reached phase 2 trials but that was it. |
|
|
|
Post by peppy on Apr 11, 2018 12:18:52 GMT -5
I find my self mistaken. I thought what Was going to look at was a nasal delivery to the mucosa.
This is a by mouth delivery, to? throat cells?
I didn't see a chemical formula, nothing.
difficult to say, what is being delivered, where.
|
|
|
|
Post by dreamboatcruise on Apr 11, 2018 16:50:52 GMT -5
I find my self mistaken. I thought what Was going to look at was a nasal delivery to the mucosa. This is a by mouth delivery, to? throat cells? I didn't see a chemical formula, nothing. difficult to say, what is being delivered, where. It's for absorption in lungs. |
|
|
|
Post by brotherm1 on Apr 11, 2018 17:57:31 GMT -5
There isn't one. I think they reached phase 2 trials but that was it. That’s great to hear! Now I feel like a dance by my ole farm. |
|
|
|
Post by digger on Apr 11, 2018 22:43:46 GMT -5
The original deal between Dance and harmony was two years ago. Then last Ausgust came -- www.bizjournals.com/prnewswire/press_releases/2017/08/29/SF76246 -- "Dance Biopharm Announces Buyback of Dance-501 Asia License from Harmony Plus Holdings." Usually when a biopharm buys back a license it's viewed as a failure, but the way this is phrased sounds optimistic: Harmony, with its extensive network in Asia, has assisted Dance in a variety of ways. Harmony was instrumental in bringing Dance an important strategic partner, Dongbao, the top Chinese insulin manufacturer and marketer in China. They also were key to the development of a regulatory pathway with the Chinese FDA that calls for China to be part of a global Phase 3 program that would enable the same regulatory documents to be used in the US, EU and China. This obviates the need for a "China alone" study and greatly facilitates bringing the product to market more efficiently. Dr. Augustine Chow and his team helped position us for success in China. We now have a single unified global Phase 3 program that includes the US, EU and China," stated John Patton, Ph.D., chairman and chief executive officer of Dance Biopharm. "Dance is extremely pleased that Harmony has agreed to continue to provide its support and advice to us for the development of Dance-501 in China under a consulting / advisory agreement." "From the first day I saw their technology, I knew they had a winner. We believe in the great potential that Dance-501 holds for the treatment of diabetes and this buyback is the result of our support for Dance's new strategy of a stronger emphasis on Asia Pacific. As shareholders of Dance Biopharm, we look forward to assisting Dance in opening the pathway toward product approval in Asia," stated Dr. Augustine Chow, Chairman of Harmony Asset Management Group." I'm not sure what to make of it. It doesn't explain why Harmony sold back the license for a product that has such "great potential." It also leaves hanging the current state of Dance's product in China. |
|
